- Home
- PCQ vs PLX Comparison
PCQ vs PLX Comparison
Compare PCQ & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCQ | PLX |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 168.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | PCQ | PLX |
|---|---|---|
| Price | $8.84 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 160.8K | ★ 578.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.36 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.16 | $1.34 |
| 52 Week High | $9.19 | $3.19 |
Technical Indicators
Market Signals| Indicator | PCQ | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 45.96 |
| Support Level | $8.81 | $1.95 |
| Resistance Level | $8.83 | $2.17 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 40.00 | 30.77 |
Price Performance
Historical ComparisonAbout PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal, New York State, and New York City income tax. The fund invests across sectors including healthcare, property, education, Natural Gas, and others.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.